Please assess the completion status of the following clinical trial:

Trial Title: Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed Langerhans cell histiocytosis (LCH) by demonstration of CD1a positivity or Birbeck granules in lesions~* Considered poor-risk, defined as multisystem disease with involvement of one or more risk organs (i.e., liver, spleen, lungs, and/or hematopoietic system)~  * No isolated lung only LCH~* Progressive disease after one of the following treatments:~  * LCH-III protocol or other standard LCH-directed therapies~ * At least 1 course of the current salvage protocol (i.e., LCH-2 2005) or similar therapy (e.g., cytosine arabinoside or cladribine-based regimens)~* HLA-matched related or unrelated donor OR unrelated umbilical cord blood (UCB) available~  * 1 locus mismatch for donor allowed~ * Up to 2 loci mismatch for unrelated UCB allowed~* Any hematologic status (transfusion support allowed)~* Adequate hepatic, renal, cardiac, and pulmonary function to undergo reduced-intensity hematopoietic cell transplantation (RI-HCT) including the following:~  * Transaminases \< 5 times upper limit of normal (ULN)~ * Bilirubin \< 3 times ULN (unless secondary to hepatic LCH)~ * Creatinine ≤ 2 mg/dL (adults) (if creatinine \> 1.2 OR history of renal dysfunction, must have estimated creatinine clearance \> 40 mL/min)~ * Creatinine clearance \> 40 mL/min (pediatrics)~ * Glomerular filtration rate ≥ 50mL/min~* Negative pregnancy test~Exclusion Criteria:~* Decompensated congestive heart failure, uncontrolled arrhythmia, or left ventricular ejection fraction ≥ 35%~* Pulmonary failure (i.e., requiring mechanical ventilation) unless secondary to active underlying LCH~* Isolated liver sclerosis or pulmonary fibrosis unless secondary to active underlying LCH~* Uncontrolled active life-threatening infection~* Pregnant or nursing~* Less than 4 weeks after last attempted salvage chemotherapy treatment~* Other concurrent chemotherapy agents (e.g., methotrexate) during entire transplantation period up to day 100 post-transplantation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab (Type: EXPERIMENTAL): Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).